DNA antibody constructs for use against pseudomonas aeruginosa
A monoclonal antibody and nucleotide sequence technology, applied in the direction of complete cells/viruses/DNA/RNA components, antibodies, DNA/RNA vaccination, etc., can solve the problem of high cost of antibody manufacturing and delivery, and must be reworked every week to every month Application and other issues
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0261] Example 1: Engineered bispecific DNA-encoded IgG antibody (DMAb) in a lethal pneumonia challenge model Pseudomonas aeruginosa
[0262] The studies presented here describe the development and in vivo production and activity analysis of synthetic DMAbs encoding the monospecific anti-PcrV IgG (DMAb-αPcrV) and the clinical candidate bispecific antibody ABC123 (DMAb-BiSPA). In vivo production of DMAbs allows rapid functional and protective titration of both constructs. These DMAbs could maintain similar potency to mAbs produced against biological processes and similarly prevent P. aeruginosa colonization of major organs.
[0263] In the current study, it was demonstrated that mAbs against Pseudomonas aeruginosa can be encoded in the synthetic DNA vector DMAb and produced in vivo by skeletal muscle. Anti-Pseudomonas DMAbs potently bind therapeutic targets and are protective in a mouse model of lethal pneumonia caused by invasive Pseudomonas aeruginosa strains. A...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com